2022 World Conference on Lung Cancer (ePosters)-EP08.02-103. Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience

EP08.02-103. Lorlatinib for ALK+ NSCLC Patients Pretreated with Second-Generation ALK Inhibitors: Canadian Real-World Experience

Back to course

Pdf Summary

A study presented at the 2022 World Conference on Lung Cancer (WCLC) evaluated the real-world use and effectiveness of lorlatinib in Canadian patients with ALK-positive non-small cell lung cancer (NSCLC) who had previously received second-generation ALK inhibitors. The study included a cohort of 59 patients who enrolled in a manufacturer-sponsored lorlatinib patient access program (PAP). The median time to discontinuation (TTD) of lorlatinib was 13.3 months, and the maximum follow-up time was 20.2 months. The TTD was consistent across different subgroups of patients, including those with different numbers of prior lines of ALK TKIs, presence of CNS metastases, and ECOG performance status. <br /><br />In addition to evaluating TTD, the study also assessed the impact of lorlatinib on quality of life (QoL) using the EQ-5D-5L health utility score (HUS) at baseline and at 3, 6, and 12 months after lorlatinib initiation. The results showed that patients experienced a statistically significant and clinically meaningful increase in QoL at 3 months compared to baseline. QoL was generally maintained for patients across all subgroups.<br /><br />The findings from this real-world study support the previous clinical trial and real-world data that demonstrated the clinical benefit of lorlatinib in the post second-generation ALK TKI setting. Despite not being publicly-reimbursed in Canada, lorlatinib was accessed through the manufacturer-sponsored PAP, providing patients with an effective treatment option. The study highlights the importance of real-world evidence in assessing the utilization and effectiveness of targeted therapies in clinical practice.

Asset Subtitle

Martin Rupp

Meta Tag

Speaker Martin Rupp

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

World Conference on Lung Cancer

lorlatinib

ALK-positive non-small cell lung cancer

second-generation ALK inhibitors

patient access program

time to discontinuation

quality of life

CNS metastases

ECOG performance status

real-world study